Anti-Fungal Treatment Market Research Report-Forecast till 2027

Anti-Fungal Treatment Market Research Report-Forecast till 2027

$4450 – $6250

The Global anti-fungal treatment market is anticipated to register a healthy CAGR of 6.35% during the review period to surpass USD 25,764.67 million by 2027.

SKU: MRFR210178 Category: Tags: , , , , ,

Description

Anti-Fungal Treatment Market Research Report—Forecast till 2027

Anti-Fungal Treatment Market Forecast
The Global anti-fungal treatment market is anticipated to register a healthy CAGR of 6.35% during the review period to surpass USD 25,764.67 million by 2027. Fungal are microorganisms that can remain alive in a wide cluster of conditions and can prompt different contaminations in the human body, going from shallow skin to foundational disease that enters the body through inward breath. These contaminations happen in the human body, generally because of high openness to unhygienic conditions of parasites or because of low safe frameworks.
The development of the worldwide antifungal treatment market is credited to the expanding episodes of fungal diseases. Different components like the expanding commonness of immunological sicknesses and the accessibility of a wide scope of items are driving the anti-fungal therapy market development. However, antifungal medicine can damage the kidney and liver and the allergic reactions caused due to antifungal medicines may hinder the market growth during the forecast period.
Market Segmentation
Anti-Fungal Treatment Market is categorized into Drug Class, therapeutic Indications, Pathogens, and end-user.
Based on drug class the global market has been classified into Azoles, Echinocandins, Polyenes, Allylamines, Pyrimidines, and Others.
By therapeutic Indications, the global antifungal treatment market is divided into Systemic, Aspergillosis, Geotrichosis, and others.
The Aspergillosis segment has further classified into Onychomycosis, Sinusitis, Keratitis, and Otomycosis.
In terms of Candidiasis, the global market has been segmented into Thrush, Mucosal Candida infections, Vaginal Candida infections, and Other Candida infections. The Cryptococcosis segment categorizes the market into Pulmonary cryptococcosis, Cryptococcal meningitis, and Others. Based on Prophylactic Use of Antifungals the global anti-fungal market has been divided into Cancer Patients, Transplantation and Abdominal Surgery Patients, Infants, and Coccidioidomycosis.
By Pathogens the global Anti-Fungal Treatment Market is segmented into Candida, Aspergillus, Cryptococcus, Coccidioides Immitis, Zygomycetes, Trichophyton, and Others
The End User segment has further been classified into Hospitals & Clinics, Dermatology Clinics, and Others.
Regional Analysis
Geographically, the global antifungal treatment market has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is likely to dominate the market having the largest market share of 40.97% market share in 2019. The regional market is driven by the high incidences of antifungal diseases, growing research spending, and the adoption of advanced treatment in the region.
Europe is expected to drive the second largest market of global antifungal treatment during the review period. The regional market is fuelled by the availability of advanced treatment facilities, increasing government initiatives to promote research to find a cure to the growing patient pool, and growing healthcare expenditure.
The antifungal treatment market in Asia-Pacific is driven by the growing R&D funding in emerging countries such as China and India for the availability of basic treatments. Additionally, the increasing prevalence of fungal infections, the increasing availability of online pharmacies, and the growing number of healthcare professionals. The market for antifungal treatment is expected to grow at a steady rate in the Middle East & Africa due to the rising number of companies and subsidiaries in the region offering treatment options.
Major Players
The prominent market players of the global Anti-Fungal Market include Pfizer Inc. (US), Astellas Pharma Ltd. (Japan), Novartis International AG (Switzerland), Sanofi S.A. (France), Merck KGaA (Germany), Bayer AG (Germany), Abbott Laboratories (US), Janssen Pharmaceuticals (US), Gilead Sciences, Inc. (US), and Cipla Inc. (India).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 2.2 RESEARCH OBJECTIVE 2.3 LIST OF ASSUMPTIONS 3 RESEARCH METHODOLOGY 3.1 OVERVIEW 3.2 DATA MINING 3.3 SECONDARY RESEARCH 3.4 PRIMARY RESEARCH 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 3.5 FORECASTING TECHNIQUES 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 3.6.1 BOTTOM-UP APPROACH 3.6.2 TOP-DOWN APPROACH 3.7 DATA TRIANGULATION 3.8 VALIDATION 4 MARKET DYNAMICS 4.1 OVERVIEW 4.2 DRIVERS 4.2.1 INCREASING INCIDENTS OF FUNGAL INFECTIONS 4.2.2 INCREASING PREVALENCE OF IMMUNOLOGICAL DISEASES IN THE ANTI-FUNGAL TREATMENT 4.2.3 AVAILABILITY OF A WIDE RANGE OF PRODUCTS 4.3 RESTRAINTS 4.3.1 SIDE-EFFECTS OF TREATMENT 4.3.2 PRESENCE OF MISBRANDED AND SPURIOUS DRUGS 4.4 OPPORTUNITIES 4.4.1 DEVELOPMENT OF NEW DRUGS 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 5.1.1 R&D AND DESIGNING 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION 5.1.4 MARKETING AND SALES 5.2 PORTER’S FIVE FORCES MODEL 5.2.1 THREAT OF NEW ENTRANTS 5.2.2 BARGAINING POWER OF SUPPLIERS 5.2.3 THREAT OF SUBSTITUTES 5.2.4 BARGAINING POWER OF BUYERS 5.2.5 RIVALRY 5.3 COVID-19 IMPACT ANALYSIS 5.3.1 IMPACT ON GLOBAL GROWTH 5.3.2 IMPACT ON MAJOR PLAYERS 5.3.3 IMPACT ON DEMAND AND SUPPLY 6 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS 6.1 OVERVIEW 6.2 AZOLES 6.3 ECHINOCANDNS 6.4 POLYENES 6.5 ALLYLAMINES 6.6 PYRIMIDINES 6.7 OTHERS 7 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY THERAPEUTIC INDICATION 7.1 OVERVIEW 7.2 SYSTEMIC 7.3 CANDIDIASIS 7.4 CRYPTOCOCCOSIS 7.5 PROPHYLACTIC USE OF ANTIFUNGALS 7.6 COCCIDIOIDOMYCOSIS 8 GLOBAL ANTI-FUNGALTREATMENT MARKET, BY PATHOGEN 8.1 OVERVIEW 8.2 CANDIDA 8.3 ASPERGILLUS 8.4 CRYPTOCOCCUS 8.5 COCCIDIOIDES IMMITIS 8.6 ZYGOMYCETES 8.7 TRICHOPHYTON 8.8 OTHERS 9 GLOBAL ANTI-FUNGALTREATMENT MARKET, BY END USERS 9.1 OVERVIEW 9.2 HOSPITALS & CLINICS 9.3 DERMATOLOGY CLINICS 9.4 OTHERS 10 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY REGION 10.1 OVERVIEW 10.2 AMERICA 10.2.1 NORTH AMERICA 10.2.1.1 U.S. 10.2.1.2 CANADA 10.2.2 SOUTH AMERICA 10.3 EUROPE 10.3.1 WESTERN EUROPE 10.3.1.1 GERMANY 10.3.1.2 FRANCE 10.3.1.3 UK 10.3.1.4 ITALY 10.3.1.5 SPAIN 10.3.1.6 REST OF WESTERN EUROPE 10.3.2 EASTERN EUROPE 10.4 ASIA PACIFIC 10.4.1 JAPAN 10.4.2 CHINA 10.4.3 INDIA 10.4.4 REPUBLIC OF KOREA 10.4.5 AUSTRALIA 10.4.6 REST OF ASIA PACIFIC 10.5 MIDDLE EAST & AFRICA 10.5.1 MIDDLE EAST 10.5.2 AFRICA 11 COMPETITIVE LANDSCAPE 11.1 OVERVIEW 11.2 COMPETITIVE BENCHMARKING 11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ANTI-FUNGAL TREATMENT MARKET 11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ANTI-FUNGAL TREATMENT MARKET 11.5 KEY DEVELOPMENT ANALYSIS 11.5.1 ACQUISITIONS 11.5.2 COLLABORATIONS/AGREEMENTS 11.5.3 EXPANSIONS 12 COMPANY PROFILES 12.1 PFIZER 12.1.1 COMPANY OVERVIEW 12.1.2 FINANCIAL OVERVIEW 12.1.3 PRODUCTS/SERVICES OFFERED 12.1.4 KEY DEVELOPMENTS 12.1.5 SWOT ANALYSIS 12.1.6 KEY STRATEGIES 12.2 ASTELLAS PHARMA LTD 12.2.1 COMPANY OVERVIEW 12.2.2 FINANCIAL OVERVIEW 12.2.3 PRODUCTS/SERVICES OFFERED 12.2.4 KEY DEVELOPMENTS 12.2.5 SWOT ANALYSIS 12.2.6 KEY STRATEGIES 12.3 NOVARTIS INTERNATIONAL AG 12.3.1 COMPANY OVERVIEW 12.3.2 FINANCIAL OVERVIEW 12.3.3 PRODUCTS/SERVICES OFFERED 12.3.4 SWOT ANALYSIS 12.3.5 KEY STRATEGIES 12.4 SANOFI S.A. 12.4.1 COMPANY OVERVIEW 12.4.2 FINANCIAL OVERVIEW 12.4.3 PRODUCTS/SERVICES OFFERED 12.4.4 KEY DEVELOPMENTS 12.4.5 SWOT ANALYSIS 12.4.6 KEY STRATEGIES 12.5 MERCK KGAA 12.5.1 COMPANY OVERVIEW 12.5.2 FINANCIAL OVERVIEW 12.5.3 PRODUCTS/SERVICES OFFERED 12.5.4 KEY DEVELOPMENTS 12.5.5 SWOT ANALYSIS 12.5.6 KEY STRATEGIES 12.6 BAYER AG 12.6.1 COMPANY OVERVIEWS 12.6.2 FINANCIAL OVERVIEW 12.6.3 PRODUCTS/SERVICES OFFERED 12.6.4 KEY DEVELOPMENTS 12.6.5 SWOT ANALYSIS 12.6.6 KEY STRATEGIES 12.7 ABBOTT LABORATORIES 12.7.1 COMPANY OVERVIEW 12.7.2 FINANCIAL OVERVIEW 12.7.3 PRODUCTS/SERVICES OFFERED 12.7.4 KEY DEVELOPMENTS 12.7.5 SWOT ANALYSIS 12.7.6 KEY STRATEGIES 12.8 JANSSEN PHARMACEUTICALS 12.8.1 COMPANY OVERVIEW 12.8.2 FINANCIAL OVERVIEW 12.8.3 PRODUCTS/SERVICES OFFERED 12.8.4 KEY DEVELOPMENTS 12.8.5 SWOT ANALYSIS 12.8.6 KEY STRATEGIES 12.9 GILEAD SCIENCES, INC. 12.9.1 COMPANY OVERVIEW 12.9.2 FINANCIAL OVERVIEW 12.9.3 PRODUCTS/SERVICES OFFERED 12.9.4 KEY DEVELOPMENTS 12.9.5 SWOT ANALYSIS 12.9.6 KEY STRATEGIES 12.10 CIPLA INC. 12.10.1 COMPANY OVERVIEW 12.10.2 FINANCIAL OVERVIEW 12.10.3 PRODUCTS/SERVICES OFFERED 12.10.4 KEY DEVELOPMENTS 12.10.5 SWOT ANALYSIS 12.10.6 KEY STRATEGIES 13 APPENDIX 13.1 REFERENCES 13.2 RELATED REPORTS

Related products